Immuneering Corp Stock Price, News & Analysis

Immuneering Corporation (Nasdaq: IMRX) successfully completed its upsized IPO, raising $129.4 million in gross proceeds, providing funding into 2024. The company expects to file an IND application for IMM-1-104, a dual-MEK inhibitor targeting RAS mutant tumors, in Q1 2022. Financial results for Q3 2021 show a cash position of $159.6 million, research expenses of $6.2 million, and a net loss of $8.5 million or $0.47 per share. The company is focused on advancing its oncology pipeline and presented promising preclinical data for IMM-1-104.

Immuneering Corporation (Nasdaq: IMRX) has revealed promising preclinical data for its lead product candidate, IMM-1-104, presented at the recent AACR-NCI-EORTC conference. The dual-MEK inhibitor showed extensive antitumor activity across various RAS and RAF mutant tumor models, including KRAS mutations. Notably, IMM-1-104 in combination with sotorasib demonstrated superior tumor regressions. The company plans to file an Investigational New Drug application with the FDA in Q1 2022, aiming to progress into human clinical trials in H1 2022.

Immuneering (Nasdaq: IMRX) announced promising preclinical data for its lead product candidate, IMM-1-104, a selective dual-MEK inhibitor targeting RAS mutant tumors. The data demonstrates broad antitumor activity and tolerability, to be presented at the AACR-NCI-EORTC conference from October 7-10, 2021. The company plans to submit an IND application to the FDA in Q1 2022. A Key Opinion Leader event is scheduled for October 12, 2021, to discuss these findings further.

Immuneering Corporation (Nasdaq: IMRX) has been included in the Russell 2000® Index as of September 20, 2021. This addition highlights the company’s successful Initial Public Offering and its dedication to oncology drug development targeting the RAS/MAPK pathway. The Russell 2000® Index includes around 2,000 small-cap companies and is widely utilized as a benchmark for investment strategies, with $9 trillion in assets linked to it. Immuneering’s focus on advancing therapies for cancer and neurological diseases is part of its robust pipeline aimed at improving patient outcomes.

Immuneering Corporation (Nasdaq: IMRX) announced the completion of an upsized initial public offering, raising $129.4 million in gross proceeds to support its pipeline. The company expects to file an IND for IMM-1-104 in Q1 2022, targeting RAS mutant tumors. As of June 30, 2021, cash and equivalents stood at $50.2 million. R&D expenses rose to $7.0 million for Q2 2021, while net loss increased to $7.9 million or $1.61 per share, compared to the previous year. Management changes were made to strengthen leadership and expand the board.

Immuneering Corporation (Nasdaq: IMRX) announced its participation in two virtual investor conferences in September 2021. Management, including CEO Ben Zeskind and CFO Biren Amin, will discuss the company’s pipeline and business strategy. The first event is Morgan Stanley’s Global Healthcare Conference, with a presentation on September 14 at 4:15 p.m. ET. The second event is Oppenheimer's Life Sciences & Med Tech Summit, with a presentation on September 21 at 4:35 p.m. ET. Both presentations will be webcast and archived for 30 days on the company’s Investor Relations website.

Immuneering Corporation (Nasdaq: IMRX) has successfully completed its upsized initial public offering, closing on 8,625,000 shares of Class A common stock at $15.00 per share, yielding approximately $129.4 million in gross proceeds. The offering included a full exercise of the underwriters' overallotment option for 1,125,000 shares. Shares commenced trading on the Nasdaq on July 30, 2021. The funds raised are aimed at enhancing Immuneering's ongoing pipeline, which focuses on innovative oncology and neuroscience treatments.

Immuneering Corporation (Nasdaq: IMRX) announced the pricing of its upsized initial public offering (IPO) of 7,500,000 shares of Class A common stock at $15.00 per share, raising total gross proceeds of $112.5 million. The offering is expected to close on August 3, 2021. There is also a 30-day option for underwriters to purchase an additional 1,125,000 shares. Shares are set to begin trading on Nasdaq on July 30, 2021. Immuneering's pipeline focuses on oncology and neuroscience, aiming to improve patient outcomes through its unique approach in drug development.

Immuneering Corporation announces the appointment of Michael Bookman as the new General Counsel and Secretary, effective immediately. Bookman brings significant legal expertise in life sciences, previously serving as General Counsel at Frequency Therapeutics. He will support the Board in governance and legal compliance as the company advances its oncology and neuroscience drug pipeline, particularly focusing on modulating cell signaling dynamics. CEO Ben Zeskind expressed confidence in Bookman's ability to guide the company through its transition into human clinical development.